Owing to the availability of an arsenal of GSK-3βinhibitorsand our interest in GSK-3β for AD,5,14,15 we sought to develop new PROTACs characterized bydifferent and previously unexplored GSK-3β recruiting elements.Particularly, we were interested to evaluate whether any differencecould be observed between an ATP competitive and non-ATP competitiveGSK-3β engagement. This evidence concerns the gene GSK3B and Alzheimer disease.